top of page
  • Writer's pictureSBIJI Innovation

BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update

August 13, 2020 

– Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020; pharmacokinetics results expected by the end of 2020

– On track for Phase 2 cosmetic clinical study of BX001 in acne first quarter of 2021

– Cash and equivalents of $70.6 million expected to fund current operating plan through mid-2022

– Company to host conference call today at 8:00 a.m. Eastern Time

BiomX Inc. (NYSE : PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2020. 

5 views0 comments

Recent Posts

See All


bottom of page